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Cyclic AMP can promote APL progression and protect
myeloid leukemia cells against anthracycline-induced
apoptosis
G Gausdal1, A Wergeland1, J Skavland2, E Nguyen3,4, F Pendino3,4, N Rouhee1, E McCormack2, L Herﬁndal1,5, R Kleppe1,
U Havemann6, F Schwede6, Ø Bruserud2,7, BT Gjertsen2,7, M Lanotte3,4, E Se´gal-Bendirdjian3,4 and SO Døskeland*,1
We show that cyclic AMP (cAMP) elevating agents protect blasts from patients with acute promyelocytic leukemia (APL) against
death induced by ﬁrst-line anti-leukemic anthracyclines like daunorubicin (DNR). The cAMP effect was reproduced in NB4 APL
cells, and shown to depend on activation of the generally cytoplasmic cAMP-kinase type I (PKA-I) rather than the perinuclear
PKA-II. The protection of both NB4 cells and APL blasts was associated with (inactivating) phosphorylation of PKA site Ser118 of
pro-apoptotic Bad and (activating) phosphorylation of PKA site Ser133 of the AML oncogene CREB. Either event would be
expected to protect broadly against cell death, and we found cAMP elevation to protect also against 2-deoxyglucose, rotenone,
proteasome inhibitor and a BH3-only mimetic. The in vitro ﬁndings were mirrored by the ﬁndings in NSG mice with orthotopic
NB4 cell leukemia. The mice showed more rapid disease progression when given cAMP-increasing agents (prostaglandin E2
analog and theophylline), both with and without DNR chemotherapy. The all-trans retinoic acid (ATRA)-induced terminal APL cell
differentiation is a cornerstone in current APL treatment and is enhanced by cAMP. We show also that ATRA-resistant APL cells,
believed to be responsible for treatment failure with current ATRA-based treatment protocols, were protected by cAMP against
death. This suggests that the beneﬁcial pro-differentiating and non-beneﬁcial pro-survival APL cell effects of cAMP should be
weighed against each other. The results suggest also general awareness toward drugs that can affect bone marrow cAMP levels
in leukemia patients.
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Cyclic AMP (cAMP) is the second messenger for extracellular
signals, such as endogenous and exogenous b-adrenergic
stimulators and members of the prostaglandin family, often
increased under conditions of inﬂammation. The cellular
cAMP concentration can also be increased by phosphodies-
terase (PDE)-inhibiting drugs. The major cAMPmediators are
the cAMP-dependent protein kinase isozyme I and II (PKA-I,
PKA-II), and the cAMP-stimulated GDP exchange factor
Epac.1,2
A striking effect of cAMP3 and the cAMP synthesis-
stimulating prostaglandin E2 (PGE2)
4 is enhanced all-trans
retinoic acid (ATRA)-induced maturation of acute promyelo-
cytic leukemia (APL)-derived NB4 cells.5 ATRA-induced
maturation is a cornerstone in APL therapy, and its combina-
tion with cAMP signaling stimulators has been advocated to
improve current APL therapy. Thus, stimulation of cAMP
signaling by PDE inhibitor enhanced the effect of ATRA on
survival of syngenic PML-RARA APL mice and mice
transplanted with NB4 cells,6–8 and retarded the APL
progression in a patient.7 Although cAMP stimulation protects
mature neutrophils9–11 and promonocytic leukemia cells12
against death and induces death of the BNML-derived AML
line IPC,13 little is known about the impact of cAMP onAPL cell
survival. This is of particular concern as ATRA is used
together with an anthracycline (daunorubicin; DNR or
idarubicin; IDA) in current APL treatment protocols.14,15
Here we used the in vivo APL model of NB4 cells
transplanted into NOD-scid IL2rgnull (NSG) mice16 to ﬁnd the
impact of cAMP-elevating agents on APL progression in the
absence and presence of DNR treatment. Animals injected
with stable PGE2 analog and cAMP phosphodiesterase
inhibitor had shortened life span both in the absence and
presence of DNR treatment. The in vitro studies showed that
the cAMP agonists protected NB4 cells against a number of
death-inducing cell stressors, including ﬁrst-line anthracycline
drugs like DNR. The protection was mediated by activation of
cAMP-dependent protein kinase type I (PKA-I), and accom-
panied by inactivating phosphorylation of the pro-apoptotic
protein Bad and activating phosphorylation of the AML proto-
oncogene CREB, both on known PKA-targeted residues.
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The clinical relevance of the NB4 model is supported by
studies of blasts from APL and AML patients, which also were
protected by cAMP against DNR-induced death in vitro. The
ﬁndings indicate awareness when patients on cAMP-elevat-
ing agents like theophylline are treated with anthracyclines, or
when cAMP stimulation is considered combined with ATRA to
boost APL cell differentiation.
Results
cAMP agonists protect NB4 APL cells against
DNR-induced death. We found that human NB4 cells,
widely accepted as being representative of human APL,5
were strongly protected by cAMP agonists against death
induced by the ﬁrst-line anti-leukemic anthracycline drug
DNR. The degree of protection (Figure 1a, main panel)
correlated with the cellular cAMP level, which was raised
more when the adenylate cyclase stimulator PGE2 was
combined with the cAMP phosphodiesterase inhibitor 3-
isobutyl-1-methylxanthine (IBMX; Figure 1a, upper right
inset). The potentiating effect of IBMX and the efﬁcacy of
the cAMP analog N6-Bz-cAMP (Figure 1a, main panel) both
indicated that the protective effect of PGE2 was mediated by
cAMP. As a prelude to intact animal studies, we found
that the stable PGE2 analog 16,16-dimethyl PGE2
(dmPGE2) synergized with any of four different cAMP
phoshodiesterase inhibitors, including the clinically relevant
compounds theophylline (aminophylline), milrinone and
rolipram (Figure 1b).
The effects could not be explained by coincidental blocking
of one or a few features of cell death, as all the death
phenotypes probed for were inhibited by cAMP, including cell
membrane blebbing (Figures 1a and b), cell size reduction
with diminished forward light scattering (Figure 1c) and
phosphatidylserine externalization (Figure 1d). cAMP stimula-
tion also prevented DNR-induced cleavage of pro-caspase 3
and the caspase target Hsp90 co-chaperone p23, known to
have a role in leukemic apoptosis13,17 (Figure 1e). In view of
reports that cAMP can affect drug transporters18,19 and
concern that cAMP might lead to intracellular sequestration
of DNR in intracellular vacuoles, we determined the total cell
and the nuclear DNR content. We found identical total DNR
concentration in cells incubated with DNR both in the absence
and presence of N6-Bz-cAMP (Figure 1f), as well as similar
intracellular distribution of DNR, with strong nuclear accumu-
lation and even cytoplasmic content (data not shown).
cAMP failed to protect the AML cell lines Mv4-11 and HL60
against DNR death, whether based on morphological assess-
ment (Figures 2a and b) or (for HL60) cleavage of p23
(Figure 2c). As cAMP agonists enhance DNR-induced cell
death in the BNML-derived rat IPC-81 cell AML model,13 we
conclude that AML cell lines differ greatly in their response to
the combination of DNR and cAMP stimulation.
cAMP agonists can protect APL and AML patient blasts
against DNR-induced death. To probe which, if any, of the
studied cell line models is relevant for human acute myeloid
leukemia, we tested leukemic blasts isolated from patients
with diagnosed APL or AML (see Supplementary Table S1
for details of disease). None of the blast isolates showed
cAMP-enhanced DNR-induced death, as observed in the
IPC cells. Rather, all the three APL blast isolates
(Figures 2d–f) and six of the seven AML blast isolates
(Figures 2g–m) resembled the NB4 cells by being protected
against DNR by PGE2/IBMX. The APL blasts had an average
of 47±5.9% (mean±S.E.M.; n¼ 3) protection and the AML
blasts 41±5.8% (n¼ 7). With N6-Bz-cAMP, the average
protection of APL blasts was 51% (data not shown). The NB4
cells appear therefore to be the most relevant cell line to
study cAMP effects on anthracycline-induced acute myeloid
leukemic blast death.
cAMP agonists protect NB4 cells under in vitro
conditions relevant for the leukemic bone marrow and
enhance APL progression in a NB4 orthotropic NSG
model. In order to better judge the intact organism
relevance, additional in vitro experiments were conducted
to cover DNR and IDA concentrations likely to be encoun-
tered in vivo20 and to mimic the hypoxic nature of leukemic
cell bone marrow niches.21 We demonstrated that cAMP
agonists protected NB4 cells also under hypoxic conditions,
and against a wide range of anthracycline concentrations
(0.1–5mM DNR and 10–500nM IDA), and for periods up to
32 h (Figure 3a, Supplementary Figure S1a).
In current standard protocols for APL treatment, DNR or
IDA is administered shortly after the onset of ATRA treatment,
Figure 1 Cyclic AMP agonists protect NB4 cells against DNR-induced cell death in proportion to the intracellular cAMP elevation, and do not interfere with DNR uptake.
(a) NB4 cells were treated for 3, 4 or 5 h with : vehicle, : DNR (5mM), : DNRþPGE2 (1.5mM, added 0.5 h before DNR), : DNRþ PGE2þ IBMX (0.3 mM, added
0.5 h before DNR) or : DNRþN6-Bz-cAMP (0.4 mM, added 0.5 h before DNR). Cell death was scored by microscopy (the inserted photomicrographs show cells treated for
5 h), and is given as mean±S.E.M., n¼ 7. Signiﬁcance by Student t-test: **Po0.01, *Po0.05, n.s.¼ not signiﬁcant. PGE2, IBMX or N6-Bz-cAMP alone had no effect on %
dead cells (data not shown). The upper right hand inset shows the cAMP level in cells treated for 1 h under some of the conditions above ( , , , ), the bars representing
the range of two experiments. (b) The cells were treated with DNR (5 mM, 5 h) in the presence or absence of dmPGE2 (1mM) together with the PDE inhibitors IBMX (0.1 mM),
theophylline (‘Aminophylline’, 0.15mM), milrinone (0.15mM) or rolipram (0.15 mM) as indicated, and cell death scored by microscopy. DmPGE2, IBMX, aminophylline,
milrinone or rolipram did not induce death alone (data not shown). The data are given as mean±S.E.M., n¼ 3. Signiﬁcance by Student t-test: **Po0.01, *Po0.05. (c) FACS
forward and side scatter analysis for size and granularity of NB4 (upper 3 panels) and NB4-LR1 (middle 3 panels) cells treated for 4 h with vehicle (Ctrl) or DNR (5 mM) in the
absence or presence of N6-Bz-cAMP (0.4 mM). The lower 3 panels show a similar analysis for NB4-LR2 cells treated for 4 h with vehicle (Ctrl) or DNR (5mM) in the absence or
presence of PGE2/IBMX (2mM/0.1mM). The data shown are representative for four separate experiments. (d) NB4 cells were treated for 4.5 h with vehicle (Ctrl) or N
6-Bz-
cAMP (0.4 mM), or with DNR (5 mM) in the absence or presence of N6-Bz-cAMP (0.4 mM) or PGE2/IBMX (2 mM/0.1mM), and analyzed for Annexin V binding by FACS.
Necrotic cells with positive PI staining (o5%) were omitted from the analyses. A representative experiment of three is shown. (e) NB4 cells were treated for 3 or 6 h with DNR
(5mM) alone or in combination with N6-Bz-cAMP (0.4 mM), and cell extracts analyzed by immunoblotting for Pro-caspase 3 and Hsp90 cochaperone p23. Actin was used as
loading control. The position of selected MW standard is indicated. (f) The strong ﬂuorescence of DNR was used to determine its concentration by ﬂow cytometry of NB4 cells
incubated for 2 or 5 h with DNR (5mM) in the presence or absence of N6-Bz-cAMP (0.4 mM). Note the lack of effect of N6-Bz-cAMP on DNR content
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and later used jointly with ATRA to eliminate ATRA-resistant
cells.15 We tested, therefore, whether cAMP agonists could
counteract the DNR-induced death both of NB4 cells starting
to undergo differentiation with ATRA (Figure 3b, left panel),
and of the ATRA-resistant sub-clones NB4-LR2 and NB4-
LR15 (Figures 1c and 3b, right panel). We found that cAMP
stimulation may protect both ATRA-primed NB4 cells and
ATRA-resistant NB4 cells against DNR in the presence of
ATRA (Figure 3b).
To know whether the cAMP agonists protected speciﬁcally
against DNR, we tested whether they also could protect
against agents promoting unfolded protein stress, like the
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proteasome inhibitor bortezomib and the HSP90 inhibitor
geldanamycin, and strong metabolic stressors like 2-deoxy-
glucose and rotenone. We found signiﬁcant protection by
cAMP against these stressors both for NB4 cells (Figure 3c)
and APL and AML blasts (Supplementary Figure S1b).
In conclusion, the elevation of cAMP is expected to promote
NB4 cell (and APL blast) survival under conditions thought to
prevail in the leukemic bone marrow both without and with
DNR therapy.
We tested, therefore, whether cAMP agonists could
promote APL cell survival also in vivo, under the assumedly
adverse conditions existing in the bone marrow under APL
invasion and the even more adverse conditions under DNR
treatment. For this purpose, we transplanted NOD-scid IL2rgnull
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Figure 2 Cyclic AMP agonists can protect APL and AML blasts against anthracycline-induced death. (a and b) Mv4-11 (a) and HL60 (b) AML cells were treated for 4 or
7 h, respectively, with DNR in the absence or presence of PGE2/IBMX (2mM/0.15mM) or N
6-Bz-cAMP (0.4 mM). The % dead cells was scored by microscopy (chromatin
condensation), and is given as mean±S.E.M., n¼ 3. Signiﬁcance by Student t-test: **Po0.01. (c) Extracts isolated from HL60 cells treated with DNR (5 mM) for 3 or 5 h
alone or in combination with PGE2/IBMX (2 mM/0.15mM) were analyzed by immunoblotting for Hsp90 cochaperone p23. Actin was used as loading control. (d–m) Blasts were
isolated from peripheral blood of three patients with diagnosed APL (APL1-APL3) and seven AML patients (AML1-AML7) and incubated with DNR alone or together with
PGE2/IBMX (2mM/0.3 mM) for 3 h (APL1, APL2 (8mM DNR)) or 24 h (APL2 (0.2 and 0.8mM DNR), APL3; AML 1–7). Samples were assessed for drug-induced cell death by
FACS analysis of PI uptake (APL1, APL 2) or by Annexin V labeling and PI uptake (APL2, APL3, AML1-AML-7). When present, PGE2/IBMX was added 0.5 h before DNR.
Further experimental details are given in the Materials and Methods section. Similar results were obtained when PGE2/IBMX was replaced by the cAMP analog N
6-Bz-cAMP
(data not shown). A Wilcoxon paired two-tailed comparison test of the ratio of dead cells after incubation with DNR alone and DNRþ either PGE2/IBMX or N6-Bz-cAMP
(0.4 mM) for all the experiments performed on the APL1-3 blasts, yielded Po0.004 for a protective effect of the cAMP agonists against Po0.007 for the AML1-7 blasts
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mice (NSG) mice with NB4 cells and injected them with
vehicle (control) or dmPGE2/theophylline. The NB4 cell-
injected animals given only vehicle survived from 31–33 days
(Figure 4a). The death was preceded by weight loss
(Figure 4b). The animals were watched for development of
extreme fatigue and/or dorsal limb paralysis before
euthanization. The animals injected with cAMP agonists had
shorter life span and more rapid weight loss than the vehicle-
injected animals (Figures 4a and b). This difference was
attributed to more rapid APL disease development, as the
timing of fatigue and paralysis relative to death was similar,
and the animals selected for autopsy showed similarly swollen
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Figure 3 Cyclic AMP-elevating agents protect NB4 cells against death induced by a number of cell stressors under conditions relevant for the leukemic bone marrow.
(a) NB4 cells were treated for various periods of time and various concentrations of DNR in the absence or presence of PGE2/IBMX (2mM/0.15mM) in standard (19% O2, 5%
CO2; solid bars) or hypoxic (2% O2, 5% CO2; hatched bars) atmosphere. The % dead cells was scored by microscopy (chromatin condensation and surface morphology), and
is given as mean±S.E.M., n¼ 3. Signiﬁcance by Student t-test: **Po0.01, *Po0.05. (b) NB4 and NB4-LR2 cells were primed with ATRA (1mM, 24 h). They were next
incubated for 5 h with DNR (D; 5 mM) or 6 h with IDA (I; 0.5mM) or vehicle in the absence or presence of PGE2/IBMX (2mM/0.1mM). The % dead cells are shown as upwards
solid bars. The % of maturated cells was determined by the nitroblue tetrazolium (NBT) reduction assay, and is given as open, downward bars. The ATRA-resistant NB4-LR2
cells were, as expected, NBT negative. The data are given as mean±S.E.M., n¼ 3. Signiﬁcance by Student t-test: **Po0.01, *Po0.05. (c) NB4 cells were treated with the
HSP90 antagonist geldanamycin (5mM), the mitochondrial toxin rotenone (5 mM), the proteasome inhibitor bortezomib (0.2mM) or the glucose antagonist 2-deoxyglucose
(10mM) for the periods of time indicated in the absence or presence of dmPGE2 (2 mM)/IBMX (0.15 mM) or dmPGE2 (2mM)/aminophylline (0.15mM). The scoring of dead
cells was as a and b
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bone marrow with brittle femurs and splenomegaly (data not
shown).
The orthotopic NSG NB4 cell APL model was also used to
test whether cAMP agonists could interfere with the effect of a
3 2.5mg/kg DNR treatment regime, designed to resemble
that used clinically in AML.14,22 The DNR treatment had a
strong survival-prolonging effect, which was signiﬁcantly
shortened for animals also receiving cAMP agonists
(Figures 4a and b). In conclusion, cAMP stimulation protects
NB4 cells against adverse in vivo conditions likely to be
encountered in the leukemic bone marrow. It also accelerates
the development of leukemia from injected NB4 cells in the
intact NSG mouse, both without and with DNR therapy.
cAMP can counteract DNR-induced NB4 cell death via
activation of PKA-I. cAMP has three major intracellular
receptors, the cAMP-binding small G protein exchange factor
Epac and the regulatory subunit of PKA-I (RIa,b) and PKA-II
(RIIa,b). We excluded Epac as mediator, as the Epac-
selective agonist23 8-CPT-20-Me-cAMP was inefﬁcient (data
not shown), whereas the PKA-selective N6-Bz-cAMP23
protected NB4 cells as efﬁciently as increased endogenous
cAMP (Figure 1).
The NB4 cell expresses both RIa and RIIa,b (Figure 5a, left
lane), with RI diffusely speckled in the cytoplasm (Figure 5b,
left panel) and RII conﬁned to the perinuclear region
(Figure 5c, left panel). The deﬁned localization of the RII
subunits, and thereby PKA-II, can channel PKA-II to a subset
of substrates,24,25 which might be essential for cAMP
protection against death. In order to probe whether PKA-II
had a speciﬁc role, we produced NB4RIIa,bKD cells by RNA-
mediated double knockdown of RIIa and RIIb.
The NB4RIIa,bKD cells lacked nearly all the RIIa and most of
the RIIb (Figures 5a and c, right panels), but had a
compensatory increase of RIa (Figure 5a, right panel) and
unchanged total PKA concentration and basal PKA activity
(data not shown). The knockdown of RIa was not undertaken,
in part because a selective inhibitor Rp-8-Br-cAMPS26 is
available, and in part because downregulation of RIa in our
hands is not compensated by RII upregulation. Hence, the
resulting excess of free cAMP-unregulated C subunit leads to
high PKA activity already in the absence of cAMP stimulation.
The NB4RIIa,bKD cells were as well protected against DNR
by N6-Bz-cAMP as the NB4wt (Figure 1) and control-
transfected NB4V0 cells (Figure 5d), indicating that activation
of PKA-I alone sufﬁces to protect. This does not exclude that
both isozymes can contribute in the NB4wt or NB4V0 cells. We
probed therefore such cells for cAMP analog pair synergy
regarding survival, using both PKA-I- and PKA-II-directed
pairs. The isozyme-speciﬁc synergy of activation is based on
their differential complementarity for binding to sites AI and BI
of PKA-I or AII and BII of PKA-II of eachmember of a pair (see
Supplementary Tables S2 and S3 for details of the analogs,
including the new 2-Cl-8-HA-cAMP). The PKA-I directed
analog pair synergized both in the NB4V0 and NB4RIIa,bKD
cells, the length of the horizontal arrows indicating the
magnitude of the analog complementarity (Figures 6a and b;
see Supplementary Figure S2a,b for alternative plots and
additional data). In contrast, the PKA-II-directed analog pair
failed to show synergism (Figure 6c, Supplementary Figure
S2c). We conclude therefore that RI subunit of PKA-I is the
cAMP receptor mediating the protective action of cAMP in
NB4 cells. The conclusion is supported by the ability of the
PKA-I-speciﬁc competitive inhibitor Rp-8-Br-cAMPS26 to
counteract the protective effect of N6-Bz-cAMP against DNR
(Figure 6d). The pivotal role of PKA suggested that the
protective action of cAMP was mediated primarily by
phosphorylation of PKA substrate(s).
The phosphorylation state of Bad and CREB in leukemic
cells exposed to DNR and cAMP agonists. PKA has a
vast number of direct substrates in the intact cell.2,27 Some of
these are convergence points between PKA and kinases
involved in general survival signaling, such as ERK and
members of the PI3-kinase cascade. They may therefore be
particularly important for cell survival. Examples are
phosphorylation of Serine 75 and 118 in the BH3-only
protein Bad28,29 (S112 and S155 in murine Bad) and Serine
133 of the transcription factor and AML oncogene CREB.30,31
We found that cAMP stimulation increased S118Bad
phosphorylation in both NB4 cells and APL3 patient blasts
(Figures 7a and b; Supplementary Figure S3a). The S118
phosphorylation liberates Bcl-2/Bcl-Xl sequestered by Bad.29
The phosphorylation of S75 of Bad was high already in non-
stimulated NB4 cells (Figure 7a). Bad was presumably
constitutively phosphorylated also on S99 in NB4 cells,
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Figure 4 cAMP enhances APL progression in an NB4 orthotropic NSG model.
(a) Survival of NB4-transplanted NOD-scid IL2rgnull mice (NSG) treated with vehicle
(‘Ctrl’, n¼ 5), dmPGE2/aminophylline (125mg/kg/20mg/kg, ‘cAMP’, n¼ 6),
daunorubicin (2.5 mg/kg, ‘DNR’, n¼ 6) or daunorubicinþ dmPGE2/aminophylline
(‘DNRþ cAMP’, n¼ 6). The group that received cAMP agonists had signiﬁcantly
(P¼ 0.003) shorter life span compared with the Ctrl group (average 32.8 against
28.8 days). DNR increased the average life span compared with the Ctrl group from
32.8 to 45.7 days, against 28.8 to 38.8 days for the DNRþ cAMP group. (b) The
weight of the NB4-transplanted NSG mice described in a relative to that (%) at the
time of NB4 cell injection. The data show the average for all mice in each group
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as their Bad migrated more slowly (apparent MWE20 kDa)
upon SDS gel electrophoresis than expected from its MW
of 18.5 kDa (Figure 7a, upper lane), a feature typical for
P-S75/S99Bad.28,32
HL60, Mv4-11 AML cells and AML3 patient blasts were not
protected by cAMP (Figures 2a, b and i) and did not show any
cAMP stimulation of S118Bad phosphorylation. In the HL60
and Mv4-11 cells, S118Bad was highly phosphorylated
already in the resting state (Figures 7c and d), and if anything,
P-S118Bad decreased slightly upon prolonged incubation
with DNR and PGE2/IBMX (Figures 7c and d). The AML3
blasts had very low Bad expression and P-S118Bad was
below the detection limit even with strong cAMP stimulation
(data not shown).
The net effect of the cAMP-stimulated S118Bad phosphory-
lation can bemodulated if cAMP also affects the expression of
other Bcl-2 family members. cAMP-stimulated NB4, HL60 or
Mv4-11 cells had unaltered level of Bax, Bcl-2 and Mcl-1
(Supplementary Figures S3 and S4), whereas DNR caused a
rapid decrease of Mcl-1 (Supplementary Figures S3b,c and
S4a–c). This suggests that DNR may promote death in all cell
lines studied by downregulating Mcl-1.
The consequence of the Mcl-1 downregulation can be
compensated by release of Bcl-2 from its complex with Bad in
cells showing cAMP-induced S118Bad phosphorylation, like
NB4 cells and APL blasts. The BH3-mimetic HA14-1 blocks
the ability of Bcl-2 to bind and neutralize Bax33 and should
therefore abolish the beneﬁcial effect of S118Bad phosphory-
lation. At maximally effective concentration (10 mM), HA14-1
induced strong NB4 cell death, which was only moderately
antagonized by cAMP (Figure 7e, left subpanel). This is
compatible with much of the protective action of cAMP being
mediated by S118Bad phosphorylation. At lower HA14-1
concentration (4 or 6mM) only moderate cell death was
observed (Figure 7e, right panel), presumably because only a
proportion of the Bcl-2 is occupied by HA14-1. Under such
conditions also the Bcl-2 liberated from Bad through S118Bad
phosphorylation will be incompletely occupied by HA14-1,
which may explain why cAMP provided robust protection
against HA14-1 at 4 and 6mM (Figure 7e, right panel).
cAMP provided some protection against DNR also in the
presence of 10 mM HA14-1 (Figure 7e, left panel), suggesting
that cAMP may protect also via other mechanisms than Bad
phosphorylation. A search for additional survival-associated
potential PKA targets by quantitative cell phospho-protein ﬂow
cytometry34 revealed increased phosphorylation of the PKA
substrate site Ser133 of CREB in NB4 cells incubated with the
PKA-directed activators PGE2/IBMX and N
6-Bz-cAMP, but
not with the Epac-directed activator 8-CPT-20-Me-cAMP
(Figure 7f). We tested next the cAMP-protected APL3 and
AML4 and the cAMP-nonresponsive AML3 patient blasts
(Figures 2f, i and j) for cAMP-induced P-S133CREB. Only in
the two cAMP-protected blasts did cAMP increase P-CREB
(Figure 7g). The broadly acting cyclin-dependent protein
kinase (CDK) 7/9 inhibitor roscovitine (RCV) blocks transcrip-
tion stimulated by CREB in a rat AML cell line13 and induces
death through transcriptional inhibition in human neutro-
phils.35 In the NB4 cells, RCV attenuated the protective effect
of cAMP stimulators against DNR (Supplementary Figure S5)
without affecting the phosphorylation of Bad (data not shown).
This supported the existence of protective actions of cAMP
involving CDK-dependent events, possibly mediated via PKA
activation of CREB.
Several other survival-related protein phosphorylation
events were studied, but were not modulated by cAMP.
ERK1/2 and PKB/Akt showed no activatory phosphorylation
(Figure 7f). The STAT transcription factors showed unaltered
phosphorylation both at sites associated with poor
(P-STAT5,34 P-STAT336) and favorable (P-STAT134) treat-
ment response in AML (Figure 7f). Furthermore, DNR or
cAMP stimulation both failed to affect the phosphorylation
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Figure 5 PKA isoenzyme II is dispensable for cAMP-mediated protection
against DNR-induced NB4 cell death. (a) Immunoblot analysis showing the effect of
knockdown of the RIIa and RIIb subunit of PKA in NB4RIIKD cells, as compared with
NB4 cells transduced with empty vector (NB4V0 cells). Note that the decline of RII
subunits in the NB4RIIKD cells is compensated by induction of RIa in the NB4RIIKD
cells. (b and c) Immunoﬂuorescence analysis showing the sub-cellular localization
of the RI (b) and RII (c) subunits of PKA in NB4V0 and NB4RIIKD cells. Note the peri-
nuclear position of the RII subunits. DAPI is used to visualize nuclear chromatin.
(d) NB4V0 and NB4RIIKD cells were treated with DNR (5mM, 5 h) alone or with N
6-
Bz-cAMP (0.4 mM), and cell death was scored. The data are given as
mean±S.E.M., n¼ 3
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of the mTOR substrates p70 S6-kinase and 4E-BP1
(Supplementary Figure S6).
We considered also that clinical, cytogenetic or other
parameters available for the APL/AML patients and their
blasts might give clues to why only the AML3 blasts failed to
be protected by cAMP. The AML3 patient has low-risk AML
based on cytogenetics (inv8) and the clinical response (full
response to induction therapy including DNR). The low-risk
status alone does not explain the lack of cAMP response,
as other blasts with low-risk cytogenetics Inv8 (AML1 and
AML4) and t8,37 (AML6) are sensitive to cAMP (Figure 2,
Supplementary Table S1). Both NPM1, p53 and Flt3, are wild
type in AML3, like for the cAMP-responsive APL3 and AML2
(Supplementary Table S1). Wild-type p53, found important for
cAMP to protect lymphoblasts against death,38 was
expressed both in the cAMP-resistant AML3 blasts and
Mv4-11 cells (see legend to Supplementary Table S1 for
details). In conclusion, cAMP protection of DNR-exposed NB4
cells and APL and AML blasts was associated with
inactivating phosphorylation of Bad and activating phosphor-
ylation of CREB.
Discussion
As cAMP stimulates ATRA-induced APL blast maturation,3–5
cAMP agonists have been considered as adjuncts to APL
therapy.6–8 In current APL therapy, an anthracycline is
combined with ATRA to eradicate APL blasts resisting
ATRA-induced maturation.15,39 We show here that cAMP
agonists accelerate APL progression inmice carrying the NB4
APL cell line and protect APL patient blasts and NB4 cells
against anthracycline-induced death in vitro. Also the ATRA-
subsensitive (NB4-LR1) and ATRA-insensitive (NB4-LR2)
APL cells were protected by cAMP against DNR. The
expected beneﬁcial effect of cAMP on APL cell maturation
may therefore be outweighed by boosted survival of ATRA-
resistant APL blasts.
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Figure 6 The relative role of PKA isoenzyme I and II to protect against DNR-induced NB4 cell death. (a and b) NB4 cells with intact PKA isozymes (NB4V0; a) or with
knocked-down RII subunits (NB4RIIKD; b) were incubated for 4 h with DNR (5 mM) and various concentrations of 2-Cl-8-HA-cAMP in the absence (, ) or presence (J,n)
of N6-Bz-8-PIP-cAMP (70 mM), which cooperates with 2-Cl-8-HA-cAMP to activate PKA-I, but not PKA-II. The percentage of dead cells dropped more rapidly when 2-Cl-
8-HA-cAMP was combined with N6-Bz-8-PIP-cAMP (horizontal arrows), indicating that selective activation of PKA-I could protect both NB4V0 and NB4RIIKD cells against
DNR. To better assess the protective synergy between the two analogs (horizontal arrow) the initial cell death was set to 100%. The data represent the average of two
experiments, and the original data are shown in Supplementary Figure S2a,b. Similar results were obtained with other PKA-I synergizing analog combinations (data not
shown). The enhanced protection with N6-Bz-8-PIP-cAMP was judged by Wilcoxon paired comparison test for the 2-Cl-8-HA-cAMP concentration range 30–600 mM, and
was found signiﬁcant (Po0.01) both for the NB4V0 and the NB4RIIKD cells. (c) NB4V0 cells were treated as described in a, except that the concentration of Sp-5,6-DCl-
cBIMPS was varied in the absence () or presence (J) of N6-MBC-cAMP (8.5mM), in order to test for PKA-II synergism. The data represent the average of two
experiments (Supplementary Figure S2c). Similar results (no synergy) were obtained with other PKA-II synergizing analog combinations (data not shown). (d) NB4WT
cells were treated for 4 h with DNR (5 mM) and increasing concentrations of N6-Bz-cAMP in the absence (’) or presence (&) of the PKA-I antagonist Rp-8-Br-cAMPS
(1 mM, added 0.5 h before DNR). The data are given as mean±S.E.M., n¼ 3. Note that much more N6-Bz-cAMP is required to protect against death in the presence of
Rp-8-Br-cAMPS. The signiﬁcance of the pairwise difference (± Rp-analog at each concentration of N6-Bz-cAMP) was evaluated by Student t-test: **Po0.01, *Po0.05
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The cAMP protected not only against the multi-targeting
anthracycline drugs,40,41 but also the glucose metabolism
antagonist 2-deoxyglucose, hypoxia/rotenone and ER stress/
misfolded protein inducers (the proteasome inhibitor bortezo-
mib and the HSP90 inhibitor geldanamycin). This may explain
why cAMP promoted APL progression also in mice not treated
with DNR, and suggests that a natural increase of bone
marrow cAMP, as may occur as a consequence of inﬂamma-
tion-induced PGE2 production42 can affect APL cell survival
also in the absence of speciﬁc treatment.
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Figure 7 The phosphorylation of Bad and CREB in cAMP- and DNR-exposed leukemic cells. (a) NB4 cells were treated with DNR (5mM) for 3 h alone or in combination
with PGE2/IBMX (2mM/0.15mM), and extracts analyzed by immunoblotting for Bad, P-Ser118Bad or P-Ser75Bad, with actin as loading control. The migration corresponding
to proteins of Mw 20 and 18.5 kDa is based on interpolation of the migration of relevant standard proteins. (b) Blasts isolated from a patient diagnosed with APL (APL3,
Supplementary Table S1) were treated in vitro for 3 h with PGE2/IBMX (2mM/0.3mM). Cell extracts were analyzed by immunoblotting for Bad and P-Ser118Bad. (c) HL60
cells were treated for 3 or 6 h with DNR (5 mM) alone or in combination with PGE2/IBMX (2mM/0.15mM), and cell extracts were analyzed by immunoblotting for Bad and
P-Ser118Bad. (d) Mv4-11 cells were treated for 5 h with DNR (0.4mM) alone or in combination with PGE2/IBMX (2 mM/0.2 mM), and cell extracts were analyzed by
immunoblotting for Bad and P-Ser118Bad. (e) The NB4 cell death was scored by microscopy after incubation with various concentrations of the BH3 mimetic HA14-1, and
DNR (3mM) and PGE2/IBMX (2 mM/0.15mM). For the left subpanel, the cells were incubated for 3.5 h with 10 mM HA14-1 either alone or during the last 3 h with DNR,
PGE2/IBMX or both. For the right hand subpanel, the incubation time with HA14-1 (4 or 6 mM) was 9.5 h, during the last 9 h with DNR, PGE2/IBMX or both. Data are shown as
mean±S.E.M., n¼ 3–6. Signiﬁcance by Student t-test: **Po0.01, *Po0.05. (f) Phospho-protein analysis by ﬂow cytometry for CREB, Erk1/2, Akt, STAT1, STAT5 and
STAT3 (see Materials and Methods for detail of phospho-residue detected). NB4 cells were incubated for 1 or 3 h with DNR (5mM), the PKA agonist N6-Bz-cAMP (0.4 mM),
the Epac agonist 8-CPT-20-Me-cAMP (0.5 mM) or the cAMP-elevating agents PGE2/IBMX (2mM/0.1mM). The phospho-epitope labeling intensity is shown as histograms (left
subpanels) and heat maps (right subpanels). The control sample was used as a baseline for the heat maps. See Materials and Methods for further experimental details.
(g) Phospho-protein analysis by ﬂow cytometry for CREB in blasts isolated from three patients (APL3, AML3 and AML4; Supplementary Table S1). Blasts were treated in vitro
for 3 h with PGE2/IBMX (2mM/0.3mM) or N
6-Bz-cAMP (0.6 mM) before ﬁxation and analysis by ﬂow cytometry. The phospho-epitope labeling intensity is shown as histograms
(left subpanels) and heat maps (right subpanels). The control sample was used as a baseline for the heat maps
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The protective effect of cAMP appeared to be mediated
by PKA rather than Epac, based on the efﬁciency of
cAMP analogs stimulating selectively either PKA or
Epac. Although the two PKA isozymes (PKA-I and PKA-II)
share the same catalytic subunit, they may serve distinct
functions due to differential cAMP sensitivity and cellular
localization.24,25 The strictly perinuclear PKA-II may have a
localized role not directly related to NB4 cell survival, as PKA-
II-directed cAMP analog combinations failed to protect
against DNR, and cAMP was fully protective in PKA-II-
depleted cells (Figures 5 and 6). In contrast, cAMP analog
pairs synergizing for PKA-I activation also synergized for
protection against DNR, and the protection afforded by a
general PKA-activating cAMP analog was counteracted by
the PKA-I-directed compound Rp-8-Br-cAMPS. That PKA-I
protects against death is not unprecedented. A PKA isozyme
switch from PKA-II to PKA-I is associated with both cellular
hypertrophy and the malignant state (see Doskeland et al.43
for review), and activation of PKA-I can protect mature
neutrophils against death.10 The possibility that PKA-I
modulates mTOR phosphorylation and thereby its activity44
appears unlikely as the mTOR substrates p70 S6-kinase and
4E-BP1 were unaffected by cAMP in the NB4 cells
(Supplementary Figure S6).
A search for prosurvival effects of PKA activation in the
cAMP-protected NB4 and APL blasts pointed to increased
phosphorylation of S118Bad and S133CREB, both of which
are recognized PKA substrate sites.29,31 PKA can thereby
turn off the Bcl-2/Bcl-Xl sequestering pro-apoptotic function of
Bad45 and activate the AML oncogene and drug resistance
factor CREB.31 In HL60 and Mv4-11 cells, where cAMP did
not confer protection, the pro-apoptotic action of Bad
appeared to be constitutively turned off, as the level of
PS118 Bad was high and not modulated further by cAMP
elevation. A number of other factors with potential to modulate
cell death were studied, but none was regulated by cAMP or
correlated with cAMP protection against DNR. Thus, cAMP-
stimulated NB4 cells showed unaltered phosphorylation of
ERK, STAT family members and mTOR kinase substrates.
Furthermore, the non-protected AML3 blasts resembled
many cAMP-protected APL/AML blasts regarding clinical
parameters, cytogenetics and expression of prognosis-
related molecules, like Flt-3, p53 wild type and NPM1
(Supplementary Table S1).
The general survival-promotion expected from Bad phos-
phorylation and CREB activation27,29 help explain the broad
cAMP-mediated protection of NB4 cells against a panel of cell
stressors. Both Bad and CREB phosphorylation are under
current investigation as therapeutic targets in AML and other
malignancies.46 The antagonism of the cAMP protection by a
BH3-only mimetic underscores further the importance and
potential druggability of the Bcl-2 family to relieve the cAMP
protection of APL cells.
Materials and Methods
Materials. The following substances were from Sigma-Aldrich (Inc., St Louis,
MO, USA): DNR, IDA, cycloheximide, RCV, 2-deoxyglucose, geldanamycin,
rotenone, ATRA, PGE2, the BH3 mimetic HA14-1, and the PDE inhibitors IBMX,
rolipram and milrinone. Bortezomib was from Millenium Pharmaceuticals, Inc
(Cambridge, MA, USA). The stabilized PGE2 analog dmPGE2 was from Cayman
Chemical (Ann Arbor, MI, USA). The PDE inhibitor theophylline (i.e., its precursor
aminophylline) was from Nycomed (Asker, Norway). The cAMP analogs
N6-benzoyl-cAMP, (N6-Bz-cAMP), Rp-8-Br-cAMPS, 8-(4-chlorophenylthio)-20-O-
methyl-cAMP (8-CPT-20-Me-cAMP), Sp-5,6-DCl-cBIMPS, N6-mono-tert-butylcar-
bamoyl-cAMP (N6-MBC-cAMP), 8-NH-CH3-cAMP, N
6-MB-cAMP, 8-CPT-cAMP, 8-
PIP-cAMP and N6-benzoyl-8-piperidino-cAMP (N6-Bz-8-PIP-cAMP) were from
Biolog Life Science Institute (Bremen, Germany). The synthesis of the new cAMP
analog 2-Cl-8-hexylamino-cAMP (2-Cl-8-HA-cAMP) was performed as previously
described for the synthesis of the related 2-Cl-8-AHA-cAMP.13
Origin of the cells used. NB4, NB4-LR1 and NB4-LR2 cells were isolated
and grown as described.3,47 NB4 cells were grown in RPMI 1640 (Sigma-Aldrich)
with 10% fetal bovine serum (Gibco, Grant Island, NY, USA), L-glutamine (2mM),
streptomycin (5 mg/ml) and penicillin (5 U/ml). Mv4-11 and HL60 cells were from
ATTC. Mv4-11 cells were grown in Iscove’s modiﬁed Dulbecco’s media (Sigma-
Aldrich Inc.) and HL60 in RPMI 1640 supplemented with 10% fetal bovine serum
(Gibco), L-glutamine (2 mM), streptomycin (5 mg/ml) and penicillin (5 U/ml). The
collection of patient cells was approved by the Regional Research Ethics
Committee (Health Region III, Bergen, Norway) and conducted in accordance with
the Declaration of Helsinki Principles. For details on patients, see Supplementary
Table S1. Samples were collected from patients shortly after the diagnosis of APL
or AML, with informed consent, and stored in bio-banks approved by the Norwegian
Ministry of Health and the Directorate for Health and Social Affairs. Primary
peripheral blood mononuclear cells were isolated by density gradient separation
(Ficoll-Hypaque; NyCoMed, Oslo, Norway); the percentage of leukemic cells after
gradient separation exceeded 95% for all patients. Cells were stored frozen in liquid
nitrogen.48 After thawing, the blasts were suspended in Stem Span medium (Stem
Cell Technologies, Vancouver, BC, Canada) before incubation with agents to be
tested for death induction.
Viral knockdown of PKA-RIIa and PKA-RIIb
Knockdown of PKA-RIIa. NB4 cells were transduced with a lentiviral plasmid
(pLKO.1/shRNA/PKAR2A, Sigma, CSHGLYC-TRCN0000037806) driving the
expression of a short hairpin RNA targeting the sequence:50-GCTGAGACCTA
TAACCCTGAT-30. The empty vector pLKO.1/TRC, given by D. E. Root (MIT,
Cambridge, MA, USA)49 was used as control (NB4V0 cells). Lentiviral particle
production, NB4 cell infection and selection of transduced NB4 cells were as
described.50
Knockdown of PKA-RIIb. NB4wt and the NB4/pLKO.1/shRNA/PKAR2A subclone
with most robust PKA-RIIa protein knockdown were silenced for PKA-RIIb
expression by the PRKA-RIIb targeting sequence (hairpin loop in small letters)
50-GGCCTTAATGTACAATACACCAGAGCAGgaccaggaccagCTGCTCTGGGTGT
ATTGTACATTAAGGCC-30 inserted in the retroviral vector RRI-Green/L071
(provided by Dr. D. Micklem and Dr. J. Lorens, University of Bergen, Norway)
downstream of a modiﬁed human U6 promoter. The one mismatch (underlined) in
the nonspeciﬁc strand served to improve the stability and efﬁcacy of the hairpin.
L071/shRNA/PKARIIB and L071/empty constructs were transfected into the
Phoenix retroviral packaging cell line to produce viral supernatants harvested
2 days after transfection. Infection of NB4 and NB4/pLKO.1/TRC cells was in the
presence of 4 mg/ml of protamine sulfate. Infected cells were sorted 9 days after
infection based on their GFP ﬂuorescence.
The NB4 orthotropic xenograft model of APL. Male NOD-scid
IL2rgnull (NSG) breeding mice were a generous gift from Dr. L. D. Shultz (Jackson
Laboratories, Bar Harbor, Maine, USA16). The animals (7- to 8-week old) received
5 106 NB4 cells (Day 0) via the tail vein. On days 4, 5 and 6 post-
transplantation, each animal received one intravenous (0.1 ml i.v.), and two
intraperitoneal (0.2 ml i.p.) injections, one 5min before and one 40min after the i.v.
injection. Group 1 (Ctr, 5 animals) received phosphate-buffered saline (PBS) both
i.v. and i.p. Group 2 (‘cAMP’, 6 animals) received PBS i.v. and a mixture of
dmPGE2 (to 125mg/kg) and aminophylline (to 20mg/kg) i.p. Group 3 (‘DNR’,
6 animals) received DNR (diluted in physiological saline to give 2.5 mg/kg) i.v. and
PBS i.p. Group 4 (‘DNRþ cAMP’, 6 animals) received both DNR and the
dmPGE2/aminophylline mixture.
The health status and weight of the mice was monitored and moribund animals
were humanely euthanized. The animal experiments were approved by The
Norwegian Animal Research Authority and performed in accordance with The
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European Convention for the Protection of Vertebrates Used for Scientiﬁc
Purposes. The survival data are presented according to Kaplan and Meier and
survival distributions analyzed by the Mantel-Cox log rank statistics, using PASW
Statistics (version 18.0).
Assessment of cell death and determination of cAMP content.
Cells (at 0.5 106/ml) were exposed to various cell death-modulating agents.
Apoptosis of cell lines was assessed mainly by microscopy to visualize surface
budding and nuclear chromatin condensation. Upon prolonged incubation with
apoptogens, some cells underwent secondary necrosis. Although swollen, such
cells retained enough of the apoptotic phenotype to be recognized as ‘dead’.
In most cases, the % of apoptoticþ (secondarily) necrotic cells is given as % dead
cells. NB4 cell lines were also studied by ﬂow cytometry on a FASC Accuri C6
(BD Biosciences, San Jose, CA, USA, Accuri Cytometry), after staining with Alexa
Fluor 647-Annexin V (Molecular Probes, Grand Island, NY, USA) and propidium
iodide (PI), and the forward and side scatter determined. At least 50 000 non-
gated live cell events were collected for each sample. The determination of
ﬂuorescence from ﬂuorescence-labeled Annexin V (binds to phosphatidyl serine) is
a challenge for cells treated with DNR, which has a strong ﬂuorescence when
excited by the 488-nm blue argon laser. We eliminated the problem by using
Annexin V coupled to the far-red Alexa Fluor 647 dye, which was excited with a
635-nm red diode and sampled in the FL-4 channel. PI gives a stronger signal
than DNR when excited at 488 nm, particularly when sampled after a long-pass
670-nm ﬁlter (FL-3). The DNR content was determined after excitation at 488 nm
and sampling in the FL-1 channel.
For primary human blasts at least 30 000 non-gated events were collected for each
sample. For the ﬁrst two samples studied (APL1,2) staining was with PI, and % PI-
positive cells taken as % death. For all other samples cell death was determined based
on the sum of Annexin VþPI-positive cells. It should be noted that the primary blasts
were more prone to (secondary) necrotic death than the cell lines and only minor
differences were observed using PI-positive and Annexin VþPI-positive cells.
For study under hypoxic conditions, the medium was pre-equilibrated for 24 h in
2% O2, 5% CO2 atmosphere. For statistical analysis, Wilcoxon Paired Comparison
test and Student’s t-Test were used.
The ATRA-induced differentiation of NB4 cells was evaluated by the nitroblue
tetrazolium reduction assay as described.47
Determination of cAMP: The cell medium was rapidly removed and cAMP
extracted in 5% trichloroacetic acid with 0.1 M HCl. The trichloroacetic acid was
extracted with acetone and the extract neutralized in phosphate-HEPES buffer
before determination of cAMP by a competitive binding assay based on
displacement of [3H]cAMP from the RIa subunit of PKA.37
Immunoblotting and immunocytoﬂuorescence. Immunoblotting
was as described.17 Proteins were detected with antibodies against,
P-Ser155Bad (murine, corresponds to human P-Ser118), Mcl-1, BAX,
Pro-caspase 3, PKA-RIIa (Santa Cruz, Biotechnology, Dallas, TX, USA), Bad,
Bcl-2, PKA-RIa, PKA-RIIb (BD Biosciences), P-Ser112Bad (murine, corresponds
to human P-Ser75; Cell Signaling, Danvers, MA, USA), p23 (mouse monoclonal
JJ3, generously supplied by Dr. D. O. Toft, Mayo Clinic, Rochester, MN, USA) or
b-actin (Amersham Biosciences, Piscataway, NJ, USA). For immunoﬂuorescence,
cells were collected by centrifugation, ﬁxed in 2% PFA in PBS (10min),
permeabilized in 0.1% Triton X-100 in PBS (10min) and blocked (2% BSA in PBS,
1 h). Incubation with anti-PKA-RI and anti-PKA-RII (in PBS-BSA) was overnight.
After washing in PBS, cells were incubated 1 h with secondary antibody Alexa
488-IgG or Alexa 594-IgG (Invitrogen), washed and mounted on slides with
Vectashield containing DAPI (Vector Laboratories, Burlingame, CA, USA). The cell
ﬂuorescence was analyzed on a Leica DMRD microscope.
Intracellular phospho-epitope staining for ﬂow cytometry. Phos-
pho-ﬂow cytometry analysis was performed as previously described.34 Alexa 647-
conjugated anti-phospho-CREB (pS133), anti-phospho-STAT1 (pY701), anti-
phospho-STAT5 (pY694), anti-phospho-STAT3 (pS727), anti-phospho-Erk1/2
(pT202/pY204) and anti-phospho-Akt (pS473) were from BD Biosciences. At
least 30 000 non-gated live cell events were collected for each sample on a FACS
Calibur (Becton Dickinson, Franklin Lakes, NJ). Normalization of ﬂow cytometry
data was performed by comparing median ﬂuorescence intensity values to an
unstimulated control using the log10 ratio of a sample divided by the control. With
this scale an increment of þ 1 corresponds to a 10-fold increase in median
ﬂuorescence intensity.
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Supplementary Figure S1a. Cyclic AMP elevating agents protect NB4 cells 
against idarubicin-induced death over a range of concentrations, incubation 
times and under oxygen tension.  
NB4 cells were treated for various periods of time and various concentrations of 
idarubicin (IDA) in the absence or presence of PGE2/IBMX (2 μM/0.15 mM) in 
standard (19 % O2, 5 % CO2; solid bars) or hypoxic (2 % O2, 5 % CO2; hatched bars) 
atmosphere. The % dead cells was scored by microscopy (chromatin condensation 
and surface morphology), and is given as mean ± SEM, n=3. Significance by Student 
t-Test: **p < 0.01, *p < 0.05. 
 
Supplementary Figure S1b. cAMP protects APL and AML blasts against cell 
death induced by geldanamycin and bortezomib. 
Some of the blasts analyzed for cAMP protection against DNR (Figure 2), namely 
APL3, AML1, AML2 and AML4, were also tested for cAMP's ability to protect 
against cell death induced by the Hsp 90 inhibitor geldanamycin and the proteasome 
inhibitor bortezomib. The blasts were incubated for 24 h with the agents shown in the 
Figure. When present, PGE2/IBMX (2 μM/0.3 mM) or N
6
-Bz-cAMP (0.6 mM) were 
added 0.5 h before geldanamycin or bortezomib. Cell samples were assessed for drug-
induced cell death by FACS analysis of AnnexinV labeling and PI uptake. 
 
Supplementary Figure S2. The relative role of PKA isoenzyme I and II to protect 
against DNR-induced cell death. 
The panels of this figure show the raw data used for panels a,b of Figure 6. (a,b) NB4 
cells with intact PKA isozymes (NB4V0; a) or with knocked-down RII subunits 
(NB4RIIKD; b) were incubated for 4 h with DNR (5 μM) and various concentrations of 
2-Cl-8-HA-cAMP in the absence ( , ) or presence ( , ) of N
6
-Bz-8-PIP-cAMP (70 
μM), which cooperates with 2-Cl-8-HA-cAMP to activate PKA-I, but not PKA-II, 
and cell death was determined. Data represent average of two experiments 
(c) NB4V0 cells were treated with DNR (5 μM, 5h) and increasing concentrations of 
Sp-5,6-DCl-cBIMPS in the absence ( ) or presence ( ) of N
6
-MBC-cAMP (8.5 μM) 
and scored for cell death. Data represent average of two experiments.  
Supplementary Figure S3. The effect of DNR and elevated cAMP on the NB4 cell 
expression of Bad, Mcl-1, Bcl-2 and BAX.  
(a) NB4 cells were treated for 4 h with DNR (5 μM) alone or in combination with 
PGE2/IBMX (2 μM/0.15 mM), and cell extracts analyzed by immunoblotting for Bad,
P-Ser118Bad and P-Ser75 Bad. Actin was used as loading control. Note the Bad 
doublet (Mw 20 and 18.5 kDa) detected with the phosphorylation-insensitive antibody 
(upper lane). Note also the virtual absence of P-S118Bad (P-S155 in murine Bad) in 
cells not treated with cAMP agonist (lane two). That P-S75Bad (lane four) was little 
affected by cAMP stimulation could be expected since most of the Bad migrated as a 
20 kDa band, rather than as a 18.5 kDa band (lane 1) This suggests that S75Bad was 
phosphorylated already in the absence of cAMP stimuylation, since phosphorylation 
of Ser75Bad (S112 in murine Bad) converts the migration of Bad, leading to the 
slowly migrating form migrating with apparent Mw = 20 kDa (1). 
(b) NB4 cells were treated with DNR (5 μM) in the absence and presence of 
PGE2/IBMX (2 μM/0.15 mM) for 3 h, and cell extract immunoblots analyzed for 
Mcl-1. Actin was used as loading control. The results shown are from one of several  
experiments with similar results. Note the lacking effect of cAMP elevating agents 
(PGE2/IBMX) on Mcl-1 expression both in the absence and presence of DNR. Similar 
results were obtained after 4 or 6 h incubation (not shown). 
(c) NB4 cells were treated with DNR (5 μM) and CHX (3.6 μM) alone or in 
combination for 1 and 4 h, and cell extracts analyzed for Mcl-1expression by 
immunoblotting. Actin was used as loading control. A typical experiment is shown. 
Lysates from cells incubated for 2 and 3 h gave similar results as after 4 h (data not 
shown). Note that the Mcl-1 level declined only slightly faster with CHX than DNR. 
(d) NB4 cells were treated as in (b) for 4, 5 and 6 h, and extracts analyzed by 
immunoblotting for Bcl-2 and BAX. Actin was used as loading control. No change of 
BAX or Bcl-2 level was observed after DNR or PGE2/IBMX treatment. 
 
Supplementary Figure S4. The effect of DNR and cAMP elevation on Bcl-2, BAX 
and Mcl-1 in HL60 and Mv4-11 cells. 
(a) HL60 cells were treated for 3 h with DNR (5 μM) alone or in combination with 
PGE2/IBMX (2 μM/0.15 mM), and cell extracts analyzed by immunoblotting for Bcl-
2, BAX and Mcl-1. Actin was used as loading control. 
(b,c) Mv4-11 cells were treated for 4 h (b) or 6 h (c) with DNR (0.4 μM) alone or in 
combination with PGE2/IBMX (2 μM/0.2 mM), and cell extracts were analyzed by 
immunoblotting for Bad, P-Ser118Bad, Bcl-2, BAX and Mcl-1. Actin was used as 
loading control. 
For a-c, note the lack of effect of cAMP elevating agents (PGE2/IBMX) on the Mcl-1 
expression both in the absence and presence of DNR. The levels of Bcl-2 and BAX 
were not influenced by DNR or PGE2/IBMX treatment. 
 
 
Supplementary Figure S5. Roscovitine partly invalidates the cAMP-mediated 
protection against DNR-induced cell death. 
NB4 cells were incubated with various combinations of DNR (5 μM), PGE2/IBMX (2 
μM/0.1 mM), N6-Bz-cAMP (0.4 mM) or RCV (10 μM) as indicated. After 5 h cells 
were fixed and scored for cell death by microscopy, shown as mean ± SEM, n = 3-4. 
Significance by Student t-Test: **p < 0.01. 
 
Supplementary Figure S6. Treatment with cAMP analog does not modulate the 
effect of DNR on mTOR substrates.   
NB4 cells were treated for 3 h with DNR (5 μM) alone or in combination with N6-Bz-
cAMP (0.4 mM), and cell lysates analyzed by immunoblotting for P-Thr37/46-4E-
BP1, 4E-BP1, P-Ser371-S6K(p70) and S6K(p70). Actin was used as loading control.  
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 Supplementary Tables  
 
Supplementary Table S1. Patient and APL/AML blast characteristics. 
Patient Age Sex Cytogenetics FAB 
classification 
P53 Flt3 NPM1 
APL1  49 F t(15;17) M3 wt wt nd 
APL2  32 M t(15;17) M3 wt ITD nd 
APL3  39 M t(15;17) M3 wt wt wt 
AML1 46 F Inv16 M1 nd wt wt 
AML2 24 M Multiple M2 wt wt wt 
AML3 48 M Inv16 M4 wt wt wt 
AML4 18 F Inv16 M4 nd wt wt 
AML5  29 M Normal M4 wt ITD ins 
AML6 47 M t(8;21) M4 nd wt wt 
AML7 29 F Normal M5 wt wt nd 
 
The age and sex is listed for the 10 patients whose APL or AML blasts were studied, 
together with cytogenetic findings, FAB classification, and p53, Flt3 and NPM1 
mutation state. ITD = internal tandem duplication, ins = insertion, nd = not 
determined. 
The patient APL1 died from intracranial hemorrhage two days after the diagnosis. 
APL2 and APL3 were treated according to the regimen described by Fenaux et al (1), 
both reached hematological remission after the induction cycle and were in molecular 
remission after the second consolidation cycle before start of maintenance therapy. 
Patient AML2 and AML7 reached complete hematological remission after two 
induction cycles, whereas patients AML1, AML3, AML4 and AML6 reached 
complete remission after the first induction cycle. Patient AML5 relapsed 11 months 
after the first remission and was then given 2 rounds of intensive chemotherapy, but 
second remission was not reached. The blasts were obtained shortly after the 
diagnosis of APL/AML, except for AML5, which were obtained after the diagnosis of 
relapse. 
Note that all 7 APL and AML patient blasts with determined p53 status had wild-type 
p53. In comparison, the cell lines studied had either deleted p53 (HL60; (2)), mutated 
p53 (NB4, (3)) or  wild type p53 (Mv4-11 (4, 5)). 
 
Supplementary Table S2. The binding affinity (relative to cAMP) to site AI and BI 
of PKA-RI and site AII, BIII of PKA-RII and lipophilicity index (LogKw) for the 
cAMP analogs used.  
 
Compound Rel.aff. AI Rel. aff. BI Rel.aff. AII Rel.aff. BII Rel. LogKw 
cAMP 1.0 1.0 1.0 1.0 1.0 
N
6
-Bz-8-PIP-cAMP 1.7 0.018 0.0011 0.065 3.0 
N6-MBC-cAMP 0.5 0.086 12.6 0.066 2.6 
2-Cl-8-AHA-cAMP 0.0052 3.9 0.0012 0.5 1.6 
2-Cl-8-HA-cAMP 0.0032 1.9 0.0034 2.2 2.6 
Sp-5,6-DCl-cBIMPS 0.022 0.13 0.034 14.0 3.0 
 
 
The cAMP analog retention on reversed phase HPLC columns relative to cAMP was 
determined as described (6) for the analogs N
6
-Bz-8-PIP-cAMP, 2-Cl-8-HA-cAMP 
and 2-Cl-8-AHA-cAMP, and reported (in bold) as LogKw, which gives a measure of 
lipophilicity and thereby the analog ability to penetrate into cells and cell 
compartments through biological membranes. The LogKw of the other analogs are 
from (6). The new analog 2-Cl-8-HA-cAMP (bold) was synthesized from 2-
chloroadenosine based on previously described strategies (7, 8). Its binding affinity 
was determined by displacement of [
3
H]cAMP from site A and B, as previously 
validated and described (9, 10). The affinity for cAMP binding sites AI, BI, AII and 
BII of the other analogs are from (10). 
Supplementary Table S3. Expected cAMP-analog pair synergy for PKA-I and 
PKA-II activation.  
cAMP analog pair (x + y) Predicted synergy PKA-I Predicted synergy PKA-II 
 
  
N6-Bz-8-PIP-cAMP+ 
2-Cl-8-AHA-cAMP 
8.41 1.31 
N
6
-Bz-8-PIP-cAMP+ 
2-Cl-8-HA-cAMP
1)
 
7.08 1.06 
8-PIP-cAMP+8-NH-CH3-cAMP 2.25 1.00 
8-CPT-cAMP + 8-AHA-cAMP 1.49 1.14 
8-PIP-cAMP + N6-MB-cAMP  1.00 2.63 
8-CPT-cAMP + N6-Bz-cAMP  1.09 3.43 
Sp-5,6-DCl-cBIMPS+    
N
6
-MBC-cAMP
2)
 
1.29 8.32 
The predicted synergy is shown between analog pairs for activation of PKA-I or 
PKA-II. Numbers above 1.0 signify synergism. The analog pairs in bold were used in 
the present study to search for PKA-I synergy
1)
 and PKA-II synergy
2)
, respectively. 
The other cAMP analog combinations entered have been used in previous studies to 
probe for PKA isozyme specific cellular events, and are shown for comparison. Note 
that they show considerable less complementarity (synergy) than the analog 
combinations used in the present study (Figure 5). The formulas used to calculate the 
synergism are explained in (11). The table shows that N
6
-Bz-8-PIP-cAMP has less 
spill-over to PKA-II activation when combined with 2-Cl-8-HA-cAMP (present 
study) than with 2-Cl-8-AHA-cAMP (10). This advantage comes in addition to the 
improved lipohilicity (see Supplementary Table S1).  
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